Zobrazeno 1 - 10
of 11
pro vyhledávání: ''
Autor:
Soo-Hwan Lee, Seo-Yoon Jeong, Min Hee Hong, Seok-Young Kim, Hye Ryun Kim, Byoung Chul Cho, Jiyeon Yun, Chae Won Park
Publikováno v:
Cancer Research. 80:5198-5198
Background: 1st generation (erlotinib & gefitinib), 2nd generation (afatinib), and 3rd generation (osimertinib) EGFR TKIs have marked efficacy in patient with EGFR-mutant NSCLC. Unfortunately, patients who show T790M (-) mutation after treated with 1
Autor:
Rebecca J. Leeman-Neill, Mark W. Lingen, Joseph S. Bednash, Raja R. Seethala, Shivendra V. Singh, William E. Gooding, Mary C. Panahandeh, Daniel B. Neill, Sonali Joyce, Jennifer R. Grandis, Maria L. Freilino, Sufi M. Thomas
Publikováno v:
Cancer Prevention Research. 4:230-237
Chemoprevention of head and neck squamous cell carcinoma (HNSCC), a disease associated with high mortality rates and frequent occurrence of second primary tumor (SPT), is an important clinical goal. The epidermal growth factor receptor (EGFR)-signal
Autor:
Erica A. Golemis, Brian L. Egleston, Hossein Borghaei, Igor Astsaturov, Mackenzie Kramer, Tetyana V. Bagnyukova
Publikováno v:
Cancer Research. 78:3469-3469
Lung cancer is the leading cause of cancer related death in the US. Patients with advanced disease generally have a poor prognosis with a median survival of around 10 to 12 months with standard chemotherapy. In patients with non-squamous non-small ce
Autor:
Elizabeth A. Maher, Balazs Halmos, Matthew Meyerson, Jeffrey C. Lee, Neal I. Lindeman, Victoria A. Joshi, Robert J. Distel, Pasi A. Jänne, Andrew M. Rogers, Ana M. Borras, Bruce E. Johnson, Hema Liyanage, Yanan Kuang
Publikováno v:
Clinical Cancer Research. 12:751-758
Purpose: Mutations in the epidermal growth factor receptor (EGFR) are associated with clinical and radiographic responses to EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Currently available methods of EGFR mutation detection rely on direc
Autor:
Fadlo R. Khuri, Victor Cohen
Publikováno v:
Clinical Cancer Research. 10:4249s-4253s
Large, randomized trials have been conducted in the primary prevention of lung cancer using micronutrients or derivative agents for which epidemiological data suggested a potential role in lung cancer prevention. The disappointing primary prevention
Autor:
Weilong Yao, Ravi Salgia, Shi-Yong Sun, Guojing Zhang, Ping Yue, Taofeek K. Owonikoko, Rajani Kanteti, Suresh S. Ramalingam, Puyu Shi, You-Take Oh, Mingwei Chen, Jacob Riehm
Publikováno v:
Cancer Research. 76:2105-2105
c-Met amplification and acquisition of a second T790M mutation are key mechanisms accounting for majority of resistant cases to first generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs; i.e., erlotinib). The third generation EGFR-TKIs (e.g., AZD92
Autor:
Jennifer Girard, Neelu Puri, Kymberly Harrington, Caleb Shearrow, Gregory M. Botting, Kavin Arasi, Zachary Crees
Publikováno v:
Cancer Research. 74:1838-1838
Current EGFR/c-Met tyrosine kinase inhibitor (TKI) combination therapies are shown to be susceptible to acquired resistance in the majority of NSCLC patients. To understand how cells develop EGFR/c-Met TKI resistance, we use three model NSCLC cell li
Autor:
Daniel Johnson, Victor Yazbeck, Kathleen A. Dorritie, Yan Zang, Changyou Li, Jennifer R. Grandis
Publikováno v:
Cancer Research. 73:2439-2439
HNSCC represents 90% of head and neck tumors. More than half of HNSCC patients are initially treated with curative intent, but will relapse over the course of their disease and have poor prognosis with a median survival of 6-9 months. Novel therapeut
Publikováno v:
Molecular Cancer Therapeutics. 10:C38-C38
Introduction: CRLX101 is a tumor-targeted nanopharmaceutical designed to localize and accumulate in tumors. A randomized Phase 2 study is ongoing evaluating safety and efficacy of CRLX101 as a second- and third-line single agent therapy for the treat
Autor:
Cheryl A. Borgman, Catharine R. Cowan, Jayme B. Stokes, Todd W. Bauer, J. Thomas Parsons, Bryce T. Lowrey, Sara J. Adair, Dustin M. Walters, Tona M. Gilmer, Edward B. Stelow
Publikováno v:
Cancer Research. 71:1592-1592
Pancreatic ductal adenocarcinoma (PDAC) is associated with the shortest survival duration of any solid cancer. To improve treatment for this disease, better understanding of the proliferative signals that drive pancreatic cancer progression is impera